Shield Thera Regulatory News (STX)

 Name of applicant:

SHIELD THERAPEUTICS PLC

Name of scheme:

Shield Therapeutics Retention Share Plan

Period of return:

From:

06 March 2020

To:

30 September 2020

Balance of unallotted securities under scheme(s) from previous return:

54,219

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

NIL

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

NIL

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

54,219

Name of applicant:

SHIELD THERAPEUTICS PLC

Name of scheme:

Shield Therapeutics plc 2016 Company Share Option Plan

Period of return:

From:

06 March 2020

To:

30 September 2020

Balance of unallotted securities under scheme(s) from previous return:

388,079

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

NIL

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

NIL

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

388,079

 Name of applicant:

SHIELD THERAPEUTICS PLC

Name of scheme:

The Shield Therapeutics plc 2016 Long Term Incentive Plan

Period of return:

From:

06 March 2020

To:

30 September 2020

Balance of unallotted securities under scheme(s) from previous return:

171,883

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

NIL

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

NIL

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

171,883 

Name of applicant:

SHIELD THERAPEUTICS PLC

Name of scheme:

Shield Therapeutics Retention and Performance Share Plan

Period of return:

From:

06 March 2020

To:

30 September 2020

Balance of unallotted securities under scheme(s) from previous return:

1,885,819

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

NIL

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

NIL

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

1,885,819

Name of contact:

Lucy Huntington-Bailey

Telephone number of contact:

+44 (0) 191 511 8500

Shield Therapeutics plc

www.shieldtherapeutics.com

Tim Watts, Chief Executive Officer

+44 (0)20 7186 8500

Lucy Huntington-Bailey, General Counsel and Company Secretary

+44 (0) 19 1511 8500

Nominated Advisor and Broker

Peel Hunt LLP

James Steel/Dr Christopher Golden

+44 (0)20 7418 8900

Joint Broker

finnCap Ltd

Geoff Nash/Matt Radley/Alice Lane

+44 (0)20 7220 0500

 Financial PR & IR Advisor

Walbrook PR

+44 (0)20 7933 8780 or shield@walbrookpr.com

Paul McManus/Lianne Cawthorne

+44 (0)7980 541 893 / +44 (0)7584 391 303